CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 18 enrolled
Drug / intervention
Prone hyperpolarized 3 helium gas scan +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03776747
NCT03776747Phase 4Completed
CompareCT.gov

Repeatability in Hyperpolarized 3-Helium Magnetic Resonance Imaging

Eric A. Hoffman·interventional·Posted Dec 17, 2018·Updated Nov 1, 2023

In Brief

A Phase 4 clinical trial evaluating Prone hyperpolarized 3 helium gas scan, Supine hyperpolarized 3 helium gas scan, and 3 other interventions for Radiation Exposure. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The main purpose of this study is to assess and test the reproducibility and results of hyperpolarized 3-Helium gas as a contrast agent with Magnetic Resonance Imaging (MRI) of the lungs in healthy adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Exposure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 17, 2018
Enrollment StartJul 22, 2008
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.5 years ago

Interventions

Prone hyperpolarized 3 helium gas scandrug

Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.

Supine hyperpolarized 3 helium gas scandrug

Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.

Vitalsother

Pulmonary Function Testsother

Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes

Initial protocol MRI scanother

Initial scan to determine placement